Form 4: Adaptive Biotechnologies Director Michelle Griffin Reports Stock Option Grant and Share Acquisition

Director Michelle Griffin of Adaptive Biotechnologies Corp. reports the acquisition of stock options and common stock, along with the disposal of common stock, in a recent SEC filing.

Summary

• On March 4, 2024, Michelle Renee Griffin, a director of Adaptive Biotechnologies Corp, reported transactions involving the company's stock.
• Griffin acquired 31,328 shares of common stock at $0 and disposed of 51,955 shares.
• Following these transactions, Griffin beneficially owns 51,955 shares of common stock.
• Griffin also acquired options to purchase 48,044 shares of common stock at an exercise price of $3.99, which vest in equal monthly installments over one year from March 4, 2024, and expire on March 4, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports transactions without providing explicit positive or negative commentary. The disposal of shares is balanced by the acquisition of options.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 51,955 shares by a director could be interpreted negatively by some investors.

Risks

• The vesting of the stock options is contingent upon continued service as a director, which introduces a risk if Griffin were to leave the company.
• Market conditions could impact the value of the acquired shares and options.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, used to align the interests of directors with those of shareholders.
• The vesting schedule of one year is fairly standard for such grants.
• The exercise price of $3.99 would need to be compared to the market price of ADPT stock at the time of the grant to assess its value.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• Employees may view the director's stock option grant as a sign of confidence in the company's future.

Key Dates